Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used as a pharmaceutical raw material. It is notable as the first orally administered GnRH receptor antagonist approved for advanced prostate cancer, offering a less burdensome option compared to injectable therapies.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 737789-87-6
6-(4-aminophenyl)-1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)thieno(2,3-d)pyrimidine-2,4(1H,3H)-dione
Pharmaceutical intermediate
Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxy-3-pyridazinyl)-6-(4-nitrophenyl)-
Pharmaceutical intermediate
Trimethoprim
Veterinary antimicrobial agent
Trans-Tramadol hydrochloride
active pharmaceutical ingredient
1,2-Dehydro Tramadol
active pharmaceutical ingredient impurity
(5E)-1alpha,25-dihydroxyvitamin D3 / (5E)-1alpha,25-dihydroxycholecalciferol
active vitamin D3 metabolite
1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
AOMXMOCNKJTRQP-UHFFFAOYSA-N
CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC